BDTX

AI Memo

Black Diamond Therapeutics

As of 2026-07-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

FDA pivotal-development-plan discussion • 2026-10-16

Expected move: +3%

Biggest risk

The data remain preliminary, the company is pre-commercial, GBM development adds execution risk, and the packet provides no usable analyst revision or market-reaction dataset to validate sustained rerating.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

Positive preliminary silevertinib efficacy, meaningful CNS activity, a potential FDA pivotal-path discussion, and runway into 2H 2028 could support rerating if clinical durability and regulatory positioning hold.

Research note

Recommendation

—

Confidence

medium

As of

2026-07-18

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

EGFRvIII-positive GBM Phase 2 execution
Cash runway limits near-term financing pressure
Positive preliminary silevertinib efficacy, meaningful CNS activity, a potential FDA pivotal-path discussion, and runway into 2H 2028 could support rerating if clinical durability and regulatory positioning hold.

BearKey bullets

FDA feedback could delay, narrow, or change the pivotal development plan.
GBM trial enrollment, safety, efficacy, or combination execution could disappoint.
No usable analyst revision set or post-release market-reaction evidence is available in the packet.

WatchKey bullets

FDA pivotal-development-plan discussion

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $2 (p=50%)

Bull/Bear spread: +56% / -47%

Vs latest close: Bull +56% · Base +3% · Bear -47%

Scenario probabilities

Bull Target: $3 (p=25%)Base Target: $2 (p=50%)Bear Target: $1 (p=25%)

Commentary

Primary-company clinical and cash-runway disclosures are constructive, but forward visibility remains limited. The packet contains only one recent Associated Press earnings item, no usable analyst revisions, no options or short-interest context, and no social coverage; therefore the thesis remains a low-coverage monitoring view rather than a high-conviction bullish call.

As of 2026-07-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

EGFRvIII-positive GBM Phase 2 execution
Cash runway limits near-term financing pressure

Scenarios

Bull Target (Scenario probability)

$3 / p=25% prob

Base Target (Scenario probability)

$2 / p=50% prob

Bear Target (Scenario probability)

$1 / p=25% prob

Price $2 as of 2026-07-17

Nearest Scenario: Base (∆ 3%)

Targets vs latest close: Bull +56% · Base +3% · Bear -47%

Sentiment & Exposure

News Sentiment (30d)

55.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-16
FDA pivotal-development-plan discussion
Management expects to meet with the FDA later in 2026 to discuss a pivotal development plan for silevertinib after reporting preliminary Phase 2 frontline NSCLC data, including 15.2-month mPFS, 60% ORR, and 86% CNS ORR [#PR-EARNINGS-2026-05-21].
Prob 65.00% • Move 20.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

EGFRvIII-positive GBM Phase 2 execution
2027-07-18
The company dosed the first patient in May 2026 in a randomized Phase 2 trial of silevertinib with temozolomide for newly diagnosed EGFRvIII-positive GBM, creating a second clinical value path but adding enrollment and execution risk [#SEC-8K-2026-05-07].
Prob 55% • Move 15% • Priced-in 40%
Cash runway limits near-term financing pressure
2027-07-18
Cash, cash equivalents, and investments were $118.3 million at March 31, 2026, with management stating that funding should support operations into the second half of 2028 [#SEC-8K-2026-05-07].
Prob 75% • Move 5% • Priced-in 70%

Risks

FDA feedback could delay, narrow, or change the pivotal development plan.
GBM trial enrollment, safety, efficacy, or combination execution could disappoint.
No usable analyst revision set or post-release market-reaction evidence is available in the packet.
Ongoing clinical development consumes cash despite the stated runway, leaving future dilution risk.
Preliminary clinical data may not translate into pivotal-trial success or approval.

Peers

Symbol	Summary
ALDX	Same-sector, similarly sized biotech comparator; useful for financing and clinical-volatility context, but not a direct EGFR-mutant NSCLC peer.
CPIX	Same-sector market-cap comparator with limited direct therapeutic overlap; relevant mainly for small-cap biotechnology risk context.
ONCY	Clinical-stage oncology comparator whose valuation is also driven by trial milestones and financing risk, though its mechanism and indication differ.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-18

AI Stock Memo: BDTX - Black Diamond Therapeutics - RankAlpha